Mesoblast (MESO) Deferred Taxes (2016 - 2024)
Mesoblast (MESO) posted Deferred Taxes of -$46000.0 for Q1 2023, up 35.21% sequentially from -$71000.0 in Q4 2022, and down 2.22% YoY from -$47045.5 in Q1 2022.
Powered by 
Analysis
Mesoblast (MESO) Deferred Taxes (2016 - 2024) Analysis & Trends
Mesoblast has reported Deferred Taxes for 8 years, with the latest figure at -$46000.0 in Q1 2023.
- Quarterly Deferred Taxes fell 2.22% year-over-year to -$46000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was -$220000.0 (up 12.7% YoY) and the FY2022 annual result came in at -$235000.0, up 71.31% from the prior year.
- Deferred Taxes climbed to -$46000.0 in Q1 2023 per MESO's latest filing, from -$71000.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at $74000.0 in Q4 2020 and troughed at -$3.3 million in Q2 2020.
- A 5-year average of -$942411.8 and a median of -$80000.0 in 2021 frame the typical range for Deferred Taxes.
- The sharpest annual moves came in 2019 and 2020: Deferred Taxes slumped 210.56% in 2019, then soared 103.26% in 2020.
- Over 5 years, Deferred Taxes stood at -$2.3 million in 2019, then soared by 103.26% to $74000.0 in 2020, then tumbled by 208.11% to -$80000.0 in 2021, then gained by 11.25% to -$71000.0 in 2022, then jumped by 35.21% to -$46000.0 in 2023.
- According to Business Quant data, Deferred Taxes over the past three periods registered -$46000.0, -$71000.0, and -$55000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -191,000.00 |
| Jun 30, 2023 | -212,000.00 |
| Mar 31, 2023 | -46,000.00 |
| Dec 31, 2022 | -71,000.00 |
| Sep 30, 2022 | -55,000.00 |
| Jun 30, 2022 | -48,000.00 |
| Mar 31, 2022 | -45,000.00 |
| Dec 31, 2021 | -80,000.00 |
| Sep 30, 2021 | -62,000.00 |
| Jun 30, 2021 | -65,000.00 |
| Mar 31, 2021 | -98,000.00 |
| Dec 31, 2020 | 74,000.00 |
| Sep 30, 2020 | -730,000.00 |
| Mar 31, 2020 | -6.16 Mn |
| Dec 31, 2019 | -4.20 Mn |
| Sep 30, 2019 | -1.93 Mn |
| Mar 31, 2019 | -2.20 Mn |
| Dec 31, 2018 | -1.64 Mn |
| Sep 30, 2018 | -711,000.00 |
| Jun 30, 2018 | -1.02 Mn |